PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.

http://ww2.peerview.com

subscribe
share






April W. Armstrong, MD, MPH / Kenneth B. Gordon, MD - Taking Aim at the TYK2 Pathway in Psoriasis: Addressing Unmet Treatment and Patient Needs With an Innovative Therapeutic Approach


Go online to PeerView.com/TWD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in psoriatic disease offer learners an in-depth look at the complex pathophysiology of psoriasis, current management paradigms, and challenges in the care of patients with moderate to severe disease. Upon completion of this accredited CE activity, participants should be better able to: Recognize the burden of disease and unmet needs experienced by patients with moderate to severe psoriasis, Discuss the rationale for blocking the JAK-STAT pathway with small molecules as a treatment approach to psoriasis, Compare and contrast novel JAK inhibitors for the treatment of psoriasis in the context of selectivity, efficacy, and safety, Treat psoriasis in accordance with current evidence and guidelines, identifying patients with moderate to severe disease, who would likely derive benefit from novel nonbiologic oral therapeutic options.


share








 2021-10-01  58m